Trial
NCT03368664
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Genzyme, a Sanofi Company
Collaborators
—
Condition
Multiple Sclerosis
Intervention
Alemtuzumab GZ402673
Why stopped
Enrolment formally closed earlier than planned due to recruitment challenges.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-26